Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.51 |
| ▸ | GRAMD1A | Q96CP6 | 5/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458456 | 1.00 | CRBN (0.51) | CRBNDDB1GRAMD1ALRRK2MAPT | |
| SCHEMBL21458594 | 1.00 | CRBN (0.51) | CRBNDDB1GRAMD1ALRRK2MAPT | |
| SCHEMBL31294841 | 0.94 | CRBN (0.53) | CRBNDDB1GRAMD1A | |
| SCHEMBL23860117 | 0.90 | CRBN (0.54) | CRBNDDB1MAPT | |
| SCHEMBL31619107 | 0.90 | CRBN (0.54) | CRBNDDB1MAPT | |
| SCHEMBL22318094 | 0.88 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL31560072 | 0.87 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL22291262 | 0.87 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL22973202 | 0.86 | CRBN (0.51) | CRBNDDB1GRAMD1ASTAT3 | |
| SCHEMBL20231478 | 0.86 | CRBN (0.55) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | CRBN 2/4885DDB1 171/4885GRAMD1A 3744/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | CRBN 2/4885DDB1 171/4885GRAMD1A 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.